Federal judges yesterday issued orders in four lawsuits over 340B program contract pharmacy policy.

New Developments in 340B Contract Pharmacy Lawsuits

Federal courts in Delaware, Indiana, and New Jersey yesterday issued orders related to the federal government’s May 17 demand to six drug manufacturers to immediately resume unrestricted 340B pricing on drugs shipped to contract pharmacies. The government asked AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics to provide an update by next Tuesday, June 1, on their plans for resuming 340B pricing when covered entities contract with outside pharmacies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »